Latest filing published 26 Feb 2016 for GLAUKOS Corp, €1.0M.
Insider track record
No signal scores available.
Montreux Equity Partners IV LP: trading record in brief
Filings by Montreux Equity Partners IV LP span 2 companies, the busiest being EPIRUS Biopharmaceuticals, Inc. and GLAUKOS Corp. In total, 10 filings cover trades dated from 22 January 2015 to 25 February 2016.
Sales make up the whole of the open-market record (8 sales, €2.3M). Since January 2016: no purchases and 1 sale on the market.
The newest entry dates from 26 February 2016: an open-market sale of €1.0M, in GLAUKOS Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Montreux Equity Partners IV LP
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 70,000 shares@ US$16.16100.0% of flowCommon StockSEC:0001104659-16-100505:0
- 3,118,406 sharesCommon StockSEC:0001104659-15-048956:0
- 161,406 sharesCommon StockSEC:0001104659-15-048956:1
- 67,316 shares@ US$4.9742Common StockSEC:0001104659-15-007692:0
- 100,000 shares@ US$5.0093Common StockSEC:0001104659-15-007692:1
- 47,000 shares@ US$4.9879Common StockSEC:0001104659-15-006930:0
- 5,684 shares@ US$4.9505Common StockSEC:0001104659-15-006930:1
- 38,516 shares@ US$6.4675Common StockSEC:0001104659-15-005035:0
- 14,130 shares@ US$6.2972Common StockSEC:0001104659-15-004406:0
- 8,400 shares@ US$6.2737Common StockSEC:0001104659-15-004406:1
10 of 10 declarations
